

**THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW**



## **BIOCARTIS ANNOUNCES EARLY CLOSING OF ITS INITIAL PUBLIC OFFERING**

**Mechelen, Belgium, 23 April 2015** – Biocartis Group NV (the “Company” or “Biocartis”), an innovative molecular diagnostics company, today announces the early closing of the offering period of its initial public offering of new shares with admission to listing on the regulated market of Euronext Brussels (the “Offering”). The Offering will now close a week ahead of schedule at 4:00 pm (CEST) today, Thursday, 23 April 2015. A press release with the results of the Offering and a revised timetable will be published tomorrow.

### **Offering**

The Offering was announced on 15 April 2015 and relates to an offering of up to 8,695,652 new shares of the Company (the “New Shares”). In addition, KBC Securities NV/SA, as stabilisation manager, on behalf of KBC Securities NV/SA, Kempen & Co N.V. and Petercam NV/SA, is expected to be granted by the Company a warrant to purchase additional new shares in an aggregate amount equal to up to 15% of the number of New Shares subscribed for in the Offering at the offer price to cover over-allotments or short positions, if any, in connection with the Offering (the “Over-allotment Option”, and the additional new shares issued pursuant to the Over-allotment Option and the New Shares collectively being referred to as the “Offered Shares”).

On 20 April 2015, the Company announced to narrow the initial price range of the Offering from between EUR 10.00 and EUR 11.50 per share to a single price of EUR 11.50 per share, being the upper end of the initial price range. The offer price of EUR 11.50 will apply to all of the Offered Shares, including the shares to be issued upon exercise of the Over-allotment Option.

The initial offering period of the Offering started on 15 April 2015 and was scheduled to run until 4:00 pm (CEST) on 29 April 2015, subject to early closing, possible as of 4:00 pm (CEST) on Wednesday, 22 April 2015, or extension. The initial offering period of the Offering will be closed earlier on 4:00 pm (CEST) on Thursday, 23 April 2015, in application of the possibility provided for in the section “The Offering” of the Prospectus (as defined below).

### **Prospectus**

A prospectus has been approved by the Belgian Financial Services and Markets Authority on 14 April 2015 (the “Prospectus”). This Prospectus is available to prospective investors in Belgium in English and Dutch. The Prospectus will be made available to prospective investors at no cost at the Company's registered office, located at Generaal De Wittelaan 11 mailbox B, 2800 Mechelen, Belgium and can be obtained by prospective investors in Belgium on request from the KBC Telecenter at +32 (0)3 283 29 70 or Petercam NV/SA at +32 (0)2 229 64 46. Subject to selling and transfer restrictions, the Prospectus is available to prospective investors in English and Dutch on the following websites: [www.biocartis.com](http://www.biocartis.com), [www.kbc.be/biocartis](http://www.kbc.be/biocartis), [www.kbcsecurities.be](http://www.kbcsecurities.be), [www.bolero.be](http://www.bolero.be) and [www.petercam.be](http://www.petercam.be).

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

An investment in the shares of the Company involves substantial risks and uncertainties, and in particular the risk that Biocartis has incurred operating losses, negative operating cash-flow and an accumulated deficit since inception and may never become profitable, risks regarding the market acceptance of Biocartis' Idylla™ platform and its menu of assays (the Idylla™ BRAF Mutation Test is the only assay that is commercialised today), risks in the development of a menu of assays and risks in relation to its (currently limited) commercialisation infrastructure. Prospective investors should read the entire Prospectus, and, in particular, should see elements D.1 and D.3 of the "Summary" and "Risk factors" for a discussion of certain factors that should be considered in connection with an investment in the Offered Shares. All of these factors should be considered before investing in the Offered Shares. Prospective investors must be able to bear the economic risk of an investment in the Offered Shares and should be able to sustain a partial or total loss of their investment.

**For more information, please contact:**

**Biocartis**

Rudi Pauwels, CEO/Hilde Windels, CFO

+32 15 632 600

[press@biocartis.com](mailto:press@biocartis.com)

**Consilium Strategic Communications**

Amber Bielecka/Jessica Hodgson/Chris Welsh/Laura Thornton

+44 (0) 203 709 5701 (London, UK)

[biocartis@consilium-comms.com](mailto:biocartis@consilium-comms.com)

**About Biocartis**

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company's proprietary MDx Idylla™ platform is a fully automated, real-time PCR (Polymerase Chain Reaction) system which offers accurate, highly-reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the estimated US\$5 billion MDx market<sup>1</sup> which is expected to grow to approximately US\$8 billion in 2018.<sup>1</sup>

---

<sup>1</sup> <http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market>

**THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW**

Biocartis employs approximately 200 people and is headquartered in Mechelen, Belgium. Further information can be found at: [www.biocartis.com](http://www.biocartis.com)

**Important information**

*The information contained in this announcement is for general information only and does not purport to be full or complete. This announcement does not constitute, or form part of, an offer to sell or issue, or any solicitation of an offer to purchase or subscribe for shares, and any purchase of, subscription for or application for, shares in the Company to be issued in connection with the Offering should only be made on the basis of information contained in the Prospectus and any supplements thereto, as the case may be. This announcement is not a Prospectus. Investors should not subscribe for any securities referred to in this document except on the basis of information contained in the Prospectus. The Prospectus contains detailed information about the Company and its management, risks associated with investing in Company, as well as financial statements and other financial data. This announcement cannot be used as basis for any investment agreement or decision.*

*This announcement is not for distribution, directly or indirectly, in or into the United States and does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the US Securities Act. The Company has not registered, and does not intend to register, any portion of the Offering of the Offered Shares in the United States, and does not intend to conduct a public offering of securities in the United States.*

*This announcement is only addressed to and directed at persons in member states of the European Economic Area ("EEA") other than Belgium who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the relevant Member State of the European Economic Area) and any implementing measure in each relevant Member State of the EEA (the "Prospectus Directive") ("Qualified Investors"). In addition, in the United Kingdom, this announcement is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") and Qualified Investors falling within Article 49(2)(a) to (d) of the Order, and (ii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). The Offering will only be available to, and any invitation, offer or agreement to subscribe for, purchase, or otherwise acquire securities will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.*

*This announcement and the information contained herein are not for publication, distribution or release in, or into, the United States, Australia, Canada, or Japan.*

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends",*

**THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW**

*"may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

*The date of completion of listing on Euronext Brussels may be influenced by things such as market conditions. There is no guarantee that such listing will occur and you should not base your financial decisions on the Company's intentions in relation to such listing at this stage. Acquiring investments to which this announcement relates may expose an investor to a significant risk of losing the entire amount invested. Persons considering such investments should consult an authorised person specialising in advising on such investments. This announcement does not constitute a recommendation concerning the Offering. The value of the shares can decrease as well as increase. Potential investors should consult a professional advisor as to the suitability of the Offering for the person concerned.*

*No announcement or information regarding the Offering or the Offered Shares may be disseminated to the public in jurisdictions outside of Belgium where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the Offering or shares of the Company in any jurisdiction outside of Belgium where such steps would be required. The issue, the subscription for or purchase of shares of the Company are subject to special legal or statutory restrictions in certain jurisdictions. The Company is not liable if the aforementioned restrictions are not complied with by any person.*

*KBC Securities NV, Kempen & Co N.V. and Petercam NV are acting for the Company and no one else in relation to the Offering, and will not be responsible to anyone other than the Company for providing the protections offered to their respective clients nor for providing advice in relation to the Offering.*

*The Company assumes responsibility for the information contained in this announcement. None of KBC Securities NV, Kempen & Co N.V. and Petercam NV or any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company its respective subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.*